Case Study: Ametris achieves nearly 90% wearable adherence in a Phase III oncology trial with ActiGraph

Ametris achieves nearly 90% wearable adherence with ActiGraph

Ametris, a Signant Health company, partnered with Johnson & Johnson Innovative Medicine on a Phase III oncology trial. Their challenge was to improve patient adherence in using ActiGraph wearable devices to collect long-term data on sleep and activity for over 12 months in an older, clinically complex patient population with metastatic prostate cancer.

ActiGraph implemented a real-time, data-driven site intervention workflow for active adherence management. This solution achieved nearly 90% adherence with sustained high daily wear time, which reduced missing data and endpoint variability. The improved data quality helped avoid costly study delays, demonstrating the value of ActiGraph's approach for long-duration oncology trials.

Ametris